跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

Selective Killing: How Chemotherapy Harms Cancer Cells More Than Normal Cells

1The Selectivity Problem: Why Preferential Killing Is Possible but Imperfect2Proliferation as the Primary Vulnerability: Cell-Cycle Dependence3Antimetabolites and the S-Phase Trap4Microtubule Poisons and Mitotic Arrest5DNA-Damaging Agents: Alkylators, Crosslinkers, and Topoisomerase Poisons6The DNA-Damage Response and the Decision to Die7Why Selectivity Fails: Normal-Tissue Toxicity and the Limits of the Window8Resistance: How Tumors Escape and What It Reveals About Selectivity9Widening the Window: Clinical Strategies That Exploit Selectivity
Widening the Window: Clinical Strategies That Exploit Selectivity

Synthetic Lethality: Turning a Repair Defect into a Target

2 / 3
Watch the two survival curves as you raise PARP inhibition. At low inhibition they sit almost on top of each other, because single-strand breaks are still being handled and neither genotype is in trouble. As inhibition climbs, the BRCA-deficient curve drops away while the BRCA-intact curve holds. The gap between them is the selectivity window, and notice what it depends on: not how fast the cells divide, but the fact that one population has already lost homologous recombination. That is the whole idea of synthetic lethality. The tumor brought one defect to the table; the drug supplies the second; only the cell holding both dies.
0:00 / 0:00

Synthetic lethality describes a pair of gene functions where losing either one alone is survivable, but losing both together kills the cell. The classic clinical example is the pairing of BRCA1 or BRCA2 loss with inhibition of poly(ADP-ribose) polymerase, or PARP, an enzyme that helps repair single-strand DNA breaks. A BRCA-mutant tumor cell has already lost homologous recombination, its high-fidelity route for repairing double-strand breaks. When PARP is inhibited, unrepaired single-strand breaks collapse into double-strand breaks at replication forks, and the tumor cell has no reliable way to fix them. A normal cell retains at least one functional BRCA allele, so it repairs those breaks by homologous recombination and survives.

This is selectivity that does not depend on proliferation rate. It depends on a tumor-specific molecular defect, which is why it is a genuine extension of the selectivity logic rather than a variation on it: instead of exploiting how fast a cell divides, we exploit what the cell has already lost. The simulation lets you vary the degree of PARP inhibition and the BRCA status of the cell population, and watch how survival separates between the two genotypes.

上一页2 / 3下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion